Cyclin-Dependent Kinase Inhibitor

1 Drug classified under this drug class

Cyclin-Dependent Kinase Inhibitor. Abemaciclib 50, 100, 150, 200 mg.
F.C TABS.: 14. When given with, the recommended dose of fulvestrant is 500 mg administered on Days 1, 15, and 29; and once mnthly. Pre/perimenopausal women treated with the comb. of Abemaciclib plus fulvestrant should be treated with a gonadotropin-releas. hormone agonist accord. to current clinic. practice standards.
When used as monotherapy, the recommended dose is 200 mg×2/d.
Cont. tmt. until dis. progres. or unaccept. toxic. Abemaciclib may be taken with / without food. For dose modif. for ADR's see lit. See lit.
In comb. with a non-steroid. aromatase inhib. as initial endocr.-based ther. for the tmt. of postmenopaus. women with hormone receptor (HR)-posit., human epiderm. growth factor receptor 2 (HER2)-neg. advanc. or metastat. breast canc.
In comb. with fulvestrant for the tmt. of women with hormone receptor (HR)-positive, human epiderm. growth fact. receptor 2 (HER2)-neg. advance. or metast. breast cancer with dis. progress. follow. endocr. ther.
As monother. for the tmt. of adult pts. with HR-posit., HER2-neg. advanc. or metastat. breast cancer with dis. progres. follow. endocr. ther. in the metastat. setting and prior chemother. in the metast. setting includ. taxane in adjuv. or metastat. setting.
Verzenio should not be used in women after prior tmt. with cyclin-depend. kinases 4 and 6 (CDK4 and CDK6) inhib.
C/I: Hypersens.